CStone and Pfizer Announce NMPA Approval of Sugemalimab in Patients with Unresectable Stage III Non-small Cell Lung Cancer

CStone Pharmaceuticals and Pfizer, Inc. announced that the National Medical Products Administration (NMPA) of China has approved sugemalimab for the treatment of patients with unresectable stage III NSCLC whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy.